Table of Content

1. Key Insights

2. Report Introduction

3. Post-traumatic stress disorder Market Overview at a Glance
3.1. Market Share (%) Distribution of Post-traumatic stress disorder in 2019
3.2. Market Share (%) Distribution of Post-traumatic stress disorder in 2032

4. Executive Summary of Post-traumatic Stress Disorder (PTSD)
4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview
6.1. Introduction
6.2. Causes of Post-traumatic Stress Disorder
6.3. Risk Factors of Post-traumatic Stress Disorder
6.4. Signs and Symptoms of Post-traumatic Stress Disorder
6.5. Clinical Manifestations of Post-traumatic Stress Disorders
6.6. Pathophysiology of Post-traumatic Stress Disorder
6.7. Medications
6.8. Comorbidities of Post-traumatic Stress Disorder

7. Diagnosis of Post-traumatic Stress Disorder
7.1. Diagnostic Criteria
7.2. Diagnostic Algorithm of Post-traumatic disorder
7.3. The Differential Diagnosis of Post-traumatic Stress Disorder

8. Treatment of Post-traumatic Stress Disorder
8.1. Psychotherapy
8.2. Treatment Algorithm

9. Diagnosis and Treatment Guidelines
9.1. American Psychological Association
9.2. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-compulsive, and Post-traumatic Stress Disorders
9.3. World Health Organization Guidelines for the Management of Conditions Specifically Related to PTSD 2013
9.4. NICE Guidelines for Post-traumatic Stress Disorder (2018)
9.5. VA/DOD Clinical Practice Guideline for the Management of Post-traumatic Stress Disorder and Acute Stress Disorder (2017)

10. Conclusion

11. Epidemiology and Patient Population
11.1. Key Findings
11.2. Epidemiology Scenario
11.2.1. Prevalence population of Post-traumatic stress disorder
11.2.2. Diagnosed prevalent Cases of Post-traumatic stress disorder
11.2.3. Gender-specific Cases of Post-traumatic stress disorder
11.2.4. Severity-specific Cases of Post-traumatic stress disorder
11.2.5. Age-specific Cases of Post-traumatic stress disorder
11.2.6. Total Treated Cases of Post-traumatic stress disorder

12. Patient Journey

13. Key Endpoints in Post-traumatic Stress Disorder (PTSD) Clinical Trials

14. Emerging Therapies
14.1. Key cross competition- Emerging Therapies
14.2. JZP150: Jazz Pharmaceuticals
14.2.1. Product Description
14.2.2. Other Developmental Activities
14.2.3. Clinical Developmental Activities
14.3. NYX-783: Aptinyx
14.3.1. Product Description
14.3.2. Other Developmental Activities
14.3.3. Clinical Developmental Activities
14.3.4. Safety and Efficacy
14.4. Rexulti (brexpiprazole) and Zoloft (sertraline) combination: Otsuka Pharmaceutical Development & Commercialization, Inc.
14.4.1. Product Description
14.4.2. Developmental activities
14.4.3. Clinical Developmental Activities
14.4.4. Safety and Efficacy
14.5. BNC210: Bionomics Limited
14.5.1. Product Description
14.5.2. Other Developmental Activities
14.5.3. Clinical Developmental Activities
14.5.4. Safety and Efficacy

15. Conjoint Analysis

16. Post-traumatic stress disorder: 7 Major Market Analysis
16.1. Key Findings

17. Market Outlook
17.1. Market Size of Post-traumatic stress disorder
17.1.1. Total Market Size of Post-traumatic stress disorder
17.1.2. Market Size of Post-traumatic stress disorder by Therapies

18. Market Access and Reimbursement
18.1. Key HTA decisions for PTSD
18.2. Patient Access Programs

19. KOL Views

20. Market Drivers
21. Market Barriers
22. SWOT Analysis
23. Unmet Needs
24. Appendix
24.1. Bibliography
24.2. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight



List of Figures

Figure 1: Epidemiology and Market Methodology
Figure 2: Understanding of Post-traumatic stress disorder
Figure 3: Causes of Post-traumatic stress disorder
Figure 4: Risk factors of Post-traumatic stress disorder
Figure 5: Signs and Symptoms of Post-traumatic stress disorder
Figure 6: Pathophysiology of Post-traumatic stress disorder
Figure 7: Treatment of Post-traumatic stress disorder
Figure 8: Comorbidities of Post-traumatic stress disorder
Figure 9: DSM-5 Diagnostic Criteria of Post-traumatic stress disorder
Figure 10: Diagnostic Algorithm of Post-traumatic stress disorder
Figure 11: Differential diagnosis of Post-traumatic stress disorder
Figure 12: Timing of treatment of Post-traumatic stress disorder
Figure 13: Treatment Algorithm of Post-traumatic stress disorder
Figure 14: Prevalent Population of Post-traumatic Stress Disorder in the 7MM (2019–2032)
Figure 15: Diagnosed Prevalent Cases of Post-traumatic Stress Disorder in the 7MM (2019–2032)
Figure 16: Gender-specific Cases of Post-traumatic Stress Disorder In the 7MM (2019–2032)
Figure 17: Severity-specific Cases of Post-traumatic Stress disorder in the 7MM (2019–2032)
Figure 18: Age-specific Cases of Post-traumatic Stress Disorder in the 7MM (2019–2032)
Figure 19: Total Treated Cases of Post-traumatic Stress Disorder in the 7MM (2019–2032)
Figure 20: Market Size of Post-traumatic Stress Disorder in the 7MM in USD Million (2019–2032)
Figure 21: 7MMMarket Size of Post-traumatic Stress Disorder (PTSD) by Therapies in USD Million (2019–2032)

List of Tables

Table 1: Prevalent Population Cases of Post-traumatic Stress Disorder in Thousands (K) (2019–2032)
Table 2: Diagnosed Prevalent Cases of Post-traumatic Stress Disorder in thousands (K) (2019–2032)
Table 3: Gender-specific Cases of Post-traumatic Stress Disorder (2019–2032)
Table 4: Severity-specific Cases of Post-traumatic stress disorder (2019–2032)
Table 5: Age-specific Cases of Post-traumatic Stress Disorder (2019–2032)
Table 6: Total Treated Cases of Post-traumatic stress disorder (2019–2032)
Table 7: Comparison of emerging drugs under development
Table 8: JZP150, Clinical Trial Description, 2022
Table 9: NYX-783, Clinical Trial Description, 2022
Table 10: Brexpiprazole + sertraline, Clinical Trial Description, 2022
Table 11: BNC210, Clinical Trial Description, 2022
Table 12: 7MM Market Size of Post-traumatic Stress Disorder in USD Million (2019–2032)
Table 13: 7MM Market Size of PTSD by Therapies in USD Million (2019–2032)
Table 14: Key HTA Decisions for PSTD